IRVINE, Calif., April 11, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Stephen Nicholls , M.B.B.S., PhD., Heart Disease Theme leader at the South Australia Health and Medical Research Institute (SAHMRI), has been appointed as chair of the newly renamed Clinical Advisory Board, replacing the recently retired Dr. Giorgio Zadini , one of the co-founders of AtheroNova. Dr. Nicholls will also be a Co-Principal Investigator in the Company's upcoming clinical trials.
"As we continue to make positive strides, this is a key step in our evolution from a pre-clinical to a clinical stage pharmaceutical company as we move toward entry into Phase 1 in the near future. Dr. Nicholls brings a wealth of experience in the imaging and analysis of cardiovascular plaque as we target the treatment of both serum cholesterol as well as atherosclerosis with AHRO-001," stated Thomas W. Gardner , CEO of AtheroNova. "Dr. Nicholls' experience with clinical developments during his time at the Cleveland Clinic as well as his new role as the key theme leader in one of the premier research organizations in Australia is essential in leading our Clinical Advisory Board. We would like to thank Dr. Zadini for all of his tremendous efforts and accomplishments as the key medical advisor of the Company during the development stage and wish him well."
"Steve is one of the world's most respected authorities in the imaging of atherosclerosis," commented Mark Wedel , M.D., Chief Medical Officer of AtheroNova. "We are profoundly fortunate and appreciative to benefit from his leadership and expertise as we move forward.
|SOURCE AtheroNova Inc.|
Copyright©2012 PR Newswire.
All rights reserved